ATE296628T1 - Integrinhemmer zur behandlung von augenkrankheiten - Google Patents

Integrinhemmer zur behandlung von augenkrankheiten

Info

Publication number
ATE296628T1
ATE296628T1 AT02748841T AT02748841T ATE296628T1 AT E296628 T1 ATE296628 T1 AT E296628T1 AT 02748841 T AT02748841 T AT 02748841T AT 02748841 T AT02748841 T AT 02748841T AT E296628 T1 ATE296628 T1 AT E296628T1
Authority
AT
Austria
Prior art keywords
treatment
eye diseases
integrin inhibitors
integrin
inhibitors
Prior art date
Application number
AT02748841T
Other languages
English (en)
Inventor
Hans Markus Bender
Jutta Haunschild
Ulrich Lang
Matthias Wiesner
Martin Friedlander
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE296628T1 publication Critical patent/ATE296628T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02748841T 2001-08-01 2002-07-03 Integrinhemmer zur behandlung von augenkrankheiten ATE296628T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01
PCT/EP2002/007377 WO2003013511A1 (en) 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
ATE296628T1 true ATE296628T1 (de) 2005-06-15

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748841T ATE296628T1 (de) 2001-08-01 2002-07-03 Integrinhemmer zur behandlung von augenkrankheiten

Country Status (20)

Country Link
US (2) US20040198644A1 (de)
EP (1) EP1411926B1 (de)
JP (1) JP2005504757A (de)
KR (1) KR20040028966A (de)
CN (1) CN1536998A (de)
AR (1) AR036199A1 (de)
AT (1) ATE296628T1 (de)
AU (1) AU2002319282B2 (de)
BR (1) BR0211604A (de)
CA (1) CA2456076C (de)
DE (1) DE60204466T2 (de)
DK (1) DK1411926T3 (de)
ES (1) ES2243744T3 (de)
HU (1) HUP0401605A3 (de)
MX (1) MXPA04000839A (de)
PL (1) PL207175B1 (de)
PT (1) PT1411926E (de)
RU (1) RU2311177C2 (de)
WO (1) WO2003013511A1 (de)
ZA (1) ZA200401598B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
JP4912881B2 (ja) * 2003-10-01 2012-04-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物
JP2008538576A (ja) * 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
WO2010113958A1 (ja) 2009-03-30 2010-10-07 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
EP2825207B1 (de) 2012-03-16 2020-08-19 The Johns Hopkins University Nichtlineare multiblock-copolymer-arzneimittelkonjugate zur verabreichung von wirkstoffen
AU2013232297B2 (en) 2012-03-16 2016-01-14 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
EP2970177A1 (de) 2013-03-15 2016-01-20 Pfizer Inc. Indolverbindungen zur ampk-aktivierung
CA2974715C (en) 2015-01-27 2020-05-05 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
JP2019501888A (ja) * 2015-12-04 2019-01-24 ヤンセン バイオテツク，インコーポレーテツド 前駆細胞を用いた網膜変性の治療
EA201991123A1 (ru) * 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
KR102307767B1 (ko) * 2019-03-11 2021-10-01 서울대학교병원 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
MX9801228A (es) * 1995-08-14 1998-05-31 Scripps Research Inst METODOS Y COMPOSICIONES UTILES PARA LA INHIBICION DE ANGIOGENESIS MEDIADA POR ALFAV beta5.
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
KR20000016301A (ko) * 1996-05-31 2000-03-25 빙검 더글라스 에이. 혈관 형성 억제에 유용한 방법 및 조성물
PT951295E (pt) * 1996-05-31 2010-07-29 Scripps Research Inst COMPOSIÎES PARA UTILIZAÆO NA INIBIÆO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
KR20040028966A (ko) 2004-04-03
BR0211604A (pt) 2004-08-24
EP1411926B1 (de) 2005-06-01
AR036199A1 (es) 2004-08-18
US20060287225A1 (en) 2006-12-21
ES2243744T3 (es) 2005-12-01
PL207175B1 (pl) 2010-11-30
WO2003013511A1 (en) 2003-02-20
JP2005504757A (ja) 2005-02-17
RU2004106527A (ru) 2005-07-10
HUP0401605A3 (en) 2012-09-28
US7645736B2 (en) 2010-01-12
PT1411926E (pt) 2005-10-31
CA2456076A1 (en) 2003-02-20
DK1411926T3 (da) 2005-08-29
CN1536998A (zh) 2004-10-13
DE60204466D1 (de) 2005-07-07
PL367959A1 (en) 2005-03-07
EP1411926A1 (de) 2004-04-28
AU2002319282B2 (en) 2007-06-28
US20040198644A1 (en) 2004-10-07
CA2456076C (en) 2011-08-23
RU2311177C2 (ru) 2007-11-27
MXPA04000839A (es) 2004-05-14
HUP0401605A2 (hu) 2004-11-29
ZA200401598B (en) 2004-11-17
DE60204466T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE451921T1 (de) Phenylindole zur behandlung von hiv
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60120961D1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411926

Country of ref document: EP